Multiple Sclerosis and Related Disorders

Emerging MS research: PIRA & prediction models 3:21
Emerging MS research: PIRA & prediction models
João José Cerqueira • 28 Oct 2022
OCT measures association with serum/CSF biomarkers in CIS patients 2:00
OCT measures association with serum/CSF biomarkers in CIS patients
Jaume Sastre-Garriga • 28 Oct 2022
Challenges with stem cell therapy in MS 2:06
Challenges with stem cell therapy in MS
João José Cerqueira • 28 Oct 2022
Biomarkers of disease activity and treatment response in MS 3:10
Biomarkers of disease activity and treatment response in MS
Mar Tintoré • 4 Nov 2022
T-cell response following COVID-19 vaccination in MS patients under treatment 1:48
T-cell response following COVID-19 vaccination in MS patients under treatment
João José Cerqueira • 28 Oct 2022
Addressing PIRA and PROMs in clinical practice 1:39
Addressing PIRA and PROMs in clinical practice
Mar Tintoré • 4 Nov 2022
The value of including optic nerve lesions in MS diagnostic criteria 1:12
The value of including optic nerve lesions in MS diagnostic criteria
Angela Vidal-Jordana • 26 Oct 2022
Autologous hematopoietic stem cell transplantation for the treatment of MS 1:12
Autologous hematopoietic stem cell transplantation for the treatment of MS
Riccardo Saccardi • 28 Oct 2022
Assisted reproductive technology treatment and the risk of MS 1:37
Assisted reproductive technology treatment and the risk of MS
Melinda Magyari • 28 Oct 2022
Long-term results of ocrelizumab in treatment-naive patients with early relapsing MS 4:32
Long-term results of ocrelizumab in treatment-naive patients with early relapsing MS
João José Cerqueira • 28 Oct 2022
Post-authorization safety study of teriflunomide in MS 1:08
Post-authorization safety study of teriflunomide in MS
Melinda Magyari • 28 Oct 2022
Using high-efficacy treatments at initial stages of MS: addressing safety concerns 1:36
Using high-efficacy treatments at initial stages of MS: addressing safety concerns
João José Cerqueira • 28 Oct 2022
Imaging highlights in MS: updated guidelines, novel markers & remyelination 1:12
Imaging highlights in MS: updated guidelines, novel markers & remyelination
Celia Oreja-Guevara • 28 Oct 2022
Relationship between UCC atrophy and brain metrics of disease activity in MS 1:35
Relationship between UCC atrophy and brain metrics of disease activity in MS
Burcu Zeydan • 27 Oct 2022
MDSA test classifies relapsing MS patients based on steroid response and disease activity status 1:04
MDSA test classifies relapsing MS patients based on steroid response and disease activity status
Ferhan Qureshi • 26 Oct 2022
Genetic contributions to MS severity to guide development of novel drugs 1:16
Genetic contributions to MS severity to guide development of novel drugs
Adil Harroud • 27 Oct 2022
The content of VJNeurology is intended for healthcare professionals